Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia

Annals of Hematology

Volumn 89, Issue 11, 2010, Pages 1073-1080

  Peñalver, Francisco Javier ^j   Alvarez Larrán, Alberto ^a   Díez Martin, Jose Luis ^b   Gallur, Laura ^c   Jarque, Isidro ^d   Caballero, Dolores ^e   Díaz Mediavilla, Joaquín ^f   Bustelos, Rosalía ^g   Fernández Aceñero, María Jesús ^h   Cabrera, José Rafael ⁱ  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h Hospital UniversitarioFundación Jiménez Díaz   (Spain)

ⁱ HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^j NONE

more..

Author keywords

Autoimmune hemolytic anemia; Refractory; Rituximab

Indexed keywords

RITUXIMAB; HEMOGLOBIN; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; COOMBS TEST; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INFECTION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RASH; REFRACTORY ANEMIA; RETROSPECTIVE STUDY; SPAIN; SPLENECTOMY; ANEMIA, HEMOLYTIC, AUTOIMMUNE; CLINICAL TRIAL; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; REMISSION; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; FEMALE; HEMOGLOBINS; HUMANS; IMMUNOLOGIC FACTORS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME; YOUNG ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; KAPLAN-MEIER ESTIMATE;

EID: 77956948998     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-0997-y     Document Type: Article

References (33)

1. BC Gehrs RC Friedberg 2002 Autoimmune hemolytic anemia Am J Hematol 69 258 271 10.1002/ajh.10062 11921020 (Pubitemid 34259848)
2. KE King PM Ness 2005 Treatment of autoimmune haemolytic anemia Semin Hematol 42 131 136 1:CAS:528:DC%2BD2MXpsFGlu7c%3D 10.1053/j.seminhematol.2005. 04.003 16041662 (Pubitemid 41019441)
3. LD Petz 2001 Treatment of autoimmune hemolytic anemias Curr Opin Hematol 8 411 416 1:STN:280:DC%2BD3Mrlsl2jtA%3D%3D 10.1097/00062752-200111000-00016 11604584 (Pubitemid 33032925)
4. B Garvey 2008 Rituximab in the treatment of autoimmune haematological disorders Br J Haematol 141 2 149 169 1:CAS:528:DC%2BD1cXlsV2muro%3D 10.1111/j.1365-2141.2008.07054.x 18318765 (Pubitemid 351406218)
5. JW Semple J Freedman 2005 Autoimmune pathogenesis and autoimmune hemolytic anemia Semin Hematol 42 122 130 1:CAS:528:DC%2BD2MXpsFGlu7Y%3D 10.1053/j.seminhematol.2005.04.002 16041661 (Pubitemid 41019440)
6. T Robak 2004 Monoclonal antibodies in the treatment of autoimmune cytopenias Eur J Haematol 72 79 88 1:CAS:528:DC%2BD2cXhslKrsrY%3D 10.1046/j.0902-4441.2003.00196.x 14962245 (Pubitemid 38161156)
7. S Berentsen E Ulvestad BT Gjertsen H Hjorth-Hansen R Langholm H Knutsen, et al. 2004 Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients Blood 103 2925 2928 1:CAS:528:DC%2BD2cXjsVahu7w%3D 10.1182/blood-2003-10-3597 15070665 (Pubitemid 38451661)
8. FJ Peñalver V Jiménez-Yuste M Almagro A Alvarez- Larrán L Rodríguez, et al. 2006 Multi-institutional Retrospective Spanish Study Group on the Use of Rituximab in Refractory ITP. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients Ann Hematol 85 6 400 406 10.1007/s00277-005-0073-1 16550390
9. S Berentsen 2007 Rituximab for the treatment of autoimmune cytopenias Haematologica 92 1589 1596 1:CAS:528:DC%2BD1cXitVWqsA%3D%3D 10.3324/haematol. 11312 18055980 (Pubitemid 350248236)
10. S Ramanathan J Koutts MS Hertzberg 2005 Two cases of refractory warm autoimmune hemolytic anemia treated with rituximab Am J Hematol 78 123 126 1:STN:280:DC%2BD2M%2FmtVOhsg%3D%3D 10.1002/ajh.20220 15682420 (Pubitemid 40194104)
11. M Zecca B Nobili U Ramenghi S Perotta G Amendola P Rosito, et al. 2003 Rituximab for the treatment of refractory autoimmune hemolytic anemia in children Blood 101 3857 3861 1:CAS:528:DC%2BD3sXktVGntL0%3D 10.1182/blood-2002- 11-3547 12531800 (Pubitemid 36857857)
12. R Stasi A Pagano E Stipa S Amadori 2001 Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura Blood 98 952 957 1:CAS:528:DC%2BD3MXmtFeis70%3D 10.1182/blood.V98.4.952 11493438
13. F Zaja I Iacona P Masolini D Russo A Sperotto S Prosdocimo, et al. 2002 B-cell depletion with rituximab as treatment for immune hemolytic anemia and thrombocytopenia Haematologica 87 189 195 1:CAS:528:DC%2BD38XivFCqsb4%3D 11836170
14. G Bussone E Ribeiro A Dechartres JF Viallard B Bonnotte, et al. 2009 Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases Am J Hematol 84 3 153 157 1:CAS:528:DC%2BD1MXktVelu7Y%3D 10.1002/ajh.21341 19123460
15. N Cooper R Stasi S Cunningham-Rundles MA Feuerstein JP Leonard S Amadori JB Bussel 2004 The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura Br J Haematol 125 232 239 1:CAS:528:DC%2BD2cXktlKrsLk%3D 10.1111/j.1365-2141.2004. 04889.x 15059147 (Pubitemid 38534976)
16. F Zaja N Vianelli A Sperotto F Patriarca M Tani L Marin, et al. 2003 Anti- CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases Leuk Lymphoma 44 1951 1955 1:CAS:528:DC%2BD3sXns1Grtbs%3D 10.1080/1042819031000119235 14738149 (Pubitemid 37369630)
17. K Kajouri SK Vesely DR Terrell JN George 2004 Splenectomy for adults patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count response, prediction of response, and surgical complications Blood 104 2623 2634 10.1182/blood-2004-03-1168 (Pubitemid 39434940)
18. R Kakaiya 2003 New therapy with anti-CD20 antibody/rituximab) for autoimmune hemolytic anemia Blood Therapies in Medicine 3 91 96
19. V Gupta A Tilak BD Bhatia 2008 Immune thrombocytopenic purpura Indian J Pediatr 75 723 728 1:STN:280:DC%2BD1crjs1yrsA%3D%3D 10.1007/s12098-008-0137-z 18716743
20. MA Gertz 2007 Management of cold haemolytic syndrome Br J Haematol 138 422 429 10.1111/j.1365-2141.2007.06664.x 17561970 (Pubitemid 47063022)
21. TD Shanafelt HL Madume RC Wolf A Tefferi 2003 Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune haemolytic anemia, and Evans syndrome Mayo Clin Proc 78 1340 1346 1:CAS:528: DC%2BD3sXpt1OgtrY%3D 10.4065/78.11.1340 14601692
22. S Berentsen E Ulvestad BT Gjertsen H Hjorth-Hansen R Langholm H Knutsen, et al. 2004 Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients Blood 103 2925 2928 1:CAS:528:DC%2BD2cXjsVahu7w%3D 10.1182/blood-2003-10-3597 15070665 (Pubitemid 38451661)
23. C Schöllkopf L Kjeldsen OW Bjerrum HT Mourits-Andersen JL Nielsen BE Christensen, et al. 2006 Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients Leuk Lymphoma 47 253 260 10.1080/ 10428190500286481 16321854 (Pubitemid 43084563)
24. D Shan JA Ledbetter OW Press 2000 Signaling events involved in anti-CD20- induced apoptosis of malignant human B cells Cancer Immunol Immunother 48 673 683 1:CAS:528:DC%2BD3cXisVaksLc%3D 10.1007/s002620050016 10752475
25. S Alas C Emmanouilides B Bonavida 2001 Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis Clin Cancer Res 7 709 723 1:CAS:528:DC%2BD3MXjtVOnsr0%3D 11297268
26. L Virgolini V Marzocchi 2004 Rituximab in autoimmune diseases Biomed Pharmacother 58 299 309 1:CAS:528:DC%2BD2cXkvVKltL0%3D 10.1016/j.biopha.2004.04. 006 15194166 (Pubitemid 38759729)
27. J Schwartz MD Leber S Gillis A Giunta A Eldor JB Bussel 2003 Long-term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP) Am J Hematol 72 94 98 10.1002/ajh.10253 12555211 (Pubitemid 36164342)
28. A Rao M Kelly M Musselman J Ramadas D Wilson W Grossman S Shenoy 2008 Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias Pediatr Blood Cancer 50 822 825 10.1002/pbc.21264 17570702 (Pubitemid 351354792)
29. E Kimby 2005 Tolerability and safety of rituximab (MabThera) Cancer Treat Rev 31 456 473 1:CAS:528:DC%2BD2MXhtFKnu7vJ 10.1016/j.ctrv.2005.05.007 16054760 (Pubitemid 41536169)
30. KL Bengston MA Skinner RE Ware 2003 Successful use of anti-CD20 (Rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura J Pediatr 143 670 673 10.1067/S0022-3476(03)00446-3 (Pubitemid 37452800)
31. HM Gürcan DB Keskin JN Stern MA Nitzberg H Shekhani AR Ahmed 2009 A review of the current use of rituximab in autoimmune diseases Int Immunopharmacol 9 1 10 25 10.1016/j.intimp.2008.10.004 19000786
32. S Aksoy H Harputluoglu S Kilickap DS Dede O Dizdar K Altundag I Barista 2007 Rituximab-related viral infections in lymphoma patients Leuk Lymphoma 48 7 1307 1312 1:CAS:528:DC%2BD2sXnsVyqs74%3D 10.1080/10428190701411441 17613758 (Pubitemid 47079357)
33. KR Carson AM Evens EA Richey, et al. 2009 Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: a report of 57 cases from the Research on Adverse Drug Event and Reports (RADAR) project Blood 113 4834 4840 1:CAS:528:DC%2BD1MXmslalsbw%3D 10.1182/blood-2008- 10-186999 19264918